Stem Cell Alopecia Treatment Market Size, Scope, Revenue, Opportunities and Growth by 2028 Shanghaiist – Shanghaiist

New Jersey, United States Stem Cell Alopecia TreatmentMarket analysis is to capture an in-depth examination of an increase in the customer journeys, which have a huge impact on market categories. It does the market classification based on region; product type and end-user to ease the market players jobs. Major industries are able to obtain key data about the whole market scenario, find out market prospects and get huge help for business operations. It further aims at providing customers deeds and their purchasing nature towards particular product or service. This sort of Stem Cell Alopecia Treatment market report provides projected trends and presents industry size for major regions to help business players make the right business plan and obtain huge earnings. It contains measured and theoretical market variable predictions. It reveals the latest industry changes by classifying the market into different sections and sub-sections.

With the help of the latest industry trends, market share, and activities provided in this Stem Cell Alopecia Treatment market analysis helps key organizations in business expansion hugely. It aids to discover the proper visions in the global market by providing insights into customer behavior, current trends, competitor analysis, and market entry strategies for novel players and strategies followed by key players. It works as the beneficial tool for the operations of several businesses. It fulfills the clients requirements and demands to increase the gains in the business.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @https://www.verifiedmarketresearch.com/download-sample/?rid=15102

Key Players Mentioned in the Stem Cell Alopecia Treatment Market Research Report:

APEX Biologix, Belgravia Center, RepliCel, Riken Research Institute, Kerastem, Sanford Burnham Prebys Medical Discovery Institute.

Stem Cell Alopecia TreatmentMarket Segmentation:

Stem Cell Alopecia Treatment Market, By Indication

Male Pattern Baldness Female Pattern Baldness Others

This Stem Cell Alopecia Treatment market report assists a number of investors, shareholders as well as enterprises in understanding the tough areas of marketing ideas, technical development, key issues, and systematic analysis in order to accomplish long-term competitive gain in the industry. It goes on to talk about basic market facets along with market drivers, restraints, existing problems, forthcoming opportunities, and forecasts. This Stem Cell Alopecia Treatment market survey depicts a few exact customer insights in order to build technology strategies to make investment useful. It makes use of both primary and secondary methods to offer wide-ranging industry data to help out you in making business choices and introducing new items to the market.

Inquire for a Discount on this Premium Report@ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=15102

For Prepare TOC Our Analyst deep Researched the Following Things:

Report Overview:It includes major players of the Stem Cell Alopecia Treatment market covered in the research study, research scope, market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the Stem Cell Alopecia Treatment market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the Stem Cell Alopecia Treatment market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the Stem Cell Alopecia Treatment market by application, it gives a study on the consumption in the Stem Cell Alopecia Treatment market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the Stem Cell Alopecia Treatment market are profiled in this section. The analysts have provided information about their recent developments in the Stem Cell Alopecia Treatment market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the Stem Cell Alopecia Treatment market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the Stem Cell Alopecia Treatment market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the Stem Cell Alopecia Treatment market.

Key Findings:This section gives a quick look at the important findings of the research study.

For More Information or Query or Customization Before Buying, Visit @ https://www.verifiedmarketresearch.com/product/stem-cell-alopecia-treatment-market/

About Us: Verified Market Research

Verified Market Research is a leading Global Research and Consulting firm that has been providing advanced analytical research solutions, custom consulting and in-depth data analysis for 10+ years to individuals and companies alike that are looking for accurate, reliable and up to date research data and technical consulting. We offer insights into strategic and growth analyses, Data necessary to achieve corporate goals and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecast, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information. The industries we cover span over a large spectrum including Technology, Chemicals, Manufacturing, Energy, Food and Beverages, Automotive, Robotics, Packaging, Construction, Mining & Gas. Etc.

We, at Verified Market Research, assist in understanding holistic market indicating factors and most current and future market trends. Our analysts, with their high expertise in data gathering and governance, utilize industry techniques to collate and examine data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research.

Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the worlds leading consulting firms like McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for businesses worldwide.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research

US: +1 (650)-781-4080 UK: +44 (753)-715-0008 APAC: +61 (488)-85-9400 US Toll-Free: +1 (800)-782-1768

Email: sales@verifiedmarketresearch.com

Website:- https://www.verifiedmarketresearch.com/

Originally posted here:
Stem Cell Alopecia Treatment Market Size, Scope, Revenue, Opportunities and Growth by 2028 Shanghaiist - Shanghaiist

COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation -…

Study cohort

In total, 38 individuals receiving SARS-CoV-2 vaccinations were recruited at the Freiburg University Medical Center, Germany. Of those, blood was collected from 31 individuals vaccinated three times with the mRNA vaccines bnt162b/Comirnaty or mRNA-1273/Spikevax and 5 individuals receiving a 4th vaccination. All vaccinees did not have a history of SARS-CoV-2 infection prior to inclusion confirmed by seronegativity for anti-SARS-CoV-2 nucleocapside IgG (anti-SARS-CoV-2 N IgG). Moreover, blood was collected from 13 individuals with SARS-CoV-2 breakthrough infections after a 3rd mRNA vaccination. Breakthrough infections were confirmed by positive PCR-testing from oropharyngeal swab. All 13 individuals with breakthrough infections included in this study had mild symptoms without respiratory insufficiency (according to WHO guidelines26). Characteristics of the participants are summarized in Supplementary Table1, including the results of the HLA-genotyping performed by next-generation sequencing.

Written informed consent was obtained from all study participants. The study was conducted in accordance to federal guidelines, local ethics committee regulations (Albert-Ludwigs-Universitt, Freiburg, Germany; vote: 322/20, 21-1135 and 315/20) and the Declaration of Helsinki (1975).

PBMCs were isolated from venous blood samples collected in EDTA blood collection tubes by density centrifugation with lymphocyte separation medium (Pancoll separation medium, PAN Biotech GmbH). PBMCs were stored at 80C until further processing. The cells were thawed in prewarmed RPMI cell culture medium supplemented with 10% fetal calf serum, 1% penicillin/streptomycin, 1.5% 1M HEPES (all purchased from Thermo Scientific) and 50U/mL Benzonase (Sigma).

Sequence homology was analyzed in Geneiousversion11.0.5 (https://www.geneious.com/) using Clustal Omega version1.2.2 alignment with default settings27. Reference genome of human ancestral SARS-CoV-2 (MN908947.3) was obtained from NCBI database. Genome sequences of SARS-CoV-2 variants of concern (VOCs) B.1, B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.1.529 BA.1 and B.1.1.529 BA.2 were identified via CoVariants (https://covariants.org/). Spike epitopes in ancestral strain and all VOCs were aligned according to their homology on an amino acid level.

Peptides were manufactured with an unmodified N-terminus and an amidated C-terminus with standard Fmoc chemistry (Genaxxon Bioscience). All peptides showed a purity of >70%. To generate tetramers, SARS-CoV-2 spike peptides (A*01/S865: LTDEMIAQY, A*02/S269: YLQPRTFLL) were loaded on biotinylated HLA class I (HLA-I) easYmer (immunAware) according to manufacturers instructions. Subsequently, peptide-loaded-HLA class I monomers were tetramerized with phycoerythrin (PE)-conjugated streptavidin according to the manufacturers instructions.

1.5 106 PBMCs were stimulated with the spike protein-derived peptides A*01/S865 or A*02/S269 and anti-CD28 monoclonal antibody (0.5g/mL) for 14 days in RPMI cell culture medium supplemented with rIL-2 (20 IU/ml, StemCell Technologies). At day 4, 7 and 11, 50% of the culture medium was exchanged with freshly prepared medium containing 20 IU/mL rIL-2. After 14 days, PBMCs were stimulated with peptides again, and stained for CD107a for 1h at 37C to analyze degranulation. Subsequently, brefeldin A (GolgiPlug, 0.5l/mL) and monensin (GolgiStop, 0.5l/mL) (all BD Biosciences) were added and incubation continued for four more hours, followed by surface and intracellular staining with anti-IFNy, anti-TNF and anti-IL-2-specific antibodies. For calculation of the expansion capacity and to assess the cytotoxic capacity of the expanded cells, peptide-loaded HLA class I tetramer staining was performed together with intracellular staining of Granzyme B, Granzyme K, Perforin and Granulysin.

CD8+ T cells targeting spike epitopes were enriched as described previously28. In brief, 5 106 to 20 106 PBMCs were stained with PE-coupled peptide-loaded HLA class I tetramers for 30min at room temperature followed by incubation with magnetic anti-PE microbeads. Subsequent positive selection of magnetically labelled cells was achieved by using MACS technology (Miltenyi Biotec) according to the manufacturers protocol. The enriched spike-specific CD8+ T cells were analyzed using multicolor flow cytometry. Cell frequencies were calculated as previously described28. Of note, only samples with 5 non-nave spike-specific CD8+ T cells were included in subsequent analyses. Accordingly, the detection limit of spike-specific CD8+ T cells in this study was 0.25 1 106, depending on the initial cell input. This cut-off number has been applied and validated in different studies on antigen-specific T cells and has shown to generate reproducible results3,11,29,30.

Antibodies used for multiparametric flow cytometry are listed in Supplementary Table2. To facilitate staining of intranuclear and cytoplasmic targets, FoxP3/Transcription Factor Staining Buffer Set (Thermo Fisher) and Fixation/Permeabilization Solution Kit (BD Biosciences) were used, respectively. Finally, cells were fixed in 2% paraformaldehyde (Sigma) and samples were analyzed on FACSCanto II or LSRFortessa with FACSDiva software version 10.6.2 (BD), or CytoFLEX (Beckman Coulter) with CytExpert Software version 2.3.0.84. Further analyses of the data were performed using FlowJo version 10.6.2 (Treestar). Phenotypical analyses were based on 5 106 to 20 106 PBMCs that were used as an input number for the magnetic bead-based enrichment of spike-specific CD8+ T cells.

For dimensionality reduction, flow cytometry data were analyzed with R version 4.1.1 and the Bioconductor CATALYST package (release 3.13)31. Initially, viable and tetramer-positive CD8+ T cells (or subsets of those) were identified using FlowJo 10 in two separate multiparametric flow cytometry panels (activation panel: HLA-DR, BCL-2, PD-1, CD137, Ki67, TCF-1, EOMES, T-BET, TOX, CD38, CD45RA, CCR7; differentiation panel: CD45RA, CCR7, CD27, CD28, CD127, CD11a, CD57, CXCR3, CD95, CD57, CD39, KLRG1, PD-1). To facilitate visualization of the dimensionality reduction by t-SNE and diffusion map analysis, cell counts were sampled down to at least 20 cells per sample, and marker expression intensities were transformed by arcsinh-transformation with a cofactor of 150.

Determination of SARS-CoV-2-specific antibodies was performed by using the Euroimmun assay Anti-SARS-CoV-2-QuantiVac-ELISA (IgG) for detecting anti-SARS-CoV-2 spike IgG (anti-SARS-CoV-2 S IgG; <35.2 BAU/mL: negative, 35.2 BAU/mL: positive) and the Mikrogen assay recomWell SARS-CoV-2 (IgG) for detecting anti-SARS-CoV-2 N IgG (detection limit, 24a.u.ml1) according to the manufacturers instructions. Data were collected with the SparkControl Magellan software version2.2.

Samples of vaccinated individuals and those with breakthrough infections were tested in a plaque reduction neutralization assay as previously described3. In brief, VeroE6 cells were seeded in 12-well plates at a density of 4 105 cells per well. Serum samples were diluted at ratios of 1:16, 1:32, 1:64, 1:128, 1:256, 1:512 and 1:1024 in a total volume of 50l PBS. For each sample, a serum-free negative control was included. Diluted sera and negative controls were subsequently mixed with 90 plaque-forming units (PFU) of authentic SARS-CoV-2 (either B.1, B.1.617.2 (delta) and B.1.1.529 BA.1 (omicron)) in 50l PBS (1,600 PFU/mL) resulting in final sera dilution ratios of 1:32, 1:64, 1:128, 1:256, 1:512, 1:1024 and 1:2048. After incubation at room temperature for 1h, 400l PBS was added to each sample and the mixture was subsequently used to infect VeroE6 cells 24h after seeding. After 1.5h of incubation at room temperature, inoculum was removed and the cells were overlaid with 0.6% Oxoid-agar in DMEM, 20mM HEPES (pH 7.4), 0.1% NaHCO3, 1% BSA and 0.01% DEAE-Dextran. Cells were fixed 72h after infection using 4% formaldehyde for 30min and stained with 1% crystal violet upon removal of the agar overlay. PFU were counted manually. Plaques counted for serum-treated wells were compared to the average number of plaques in the untreated negative controls, which were set to 100%. Calculation of PRNT50 values was performed using a linear regression model in GraphPad Prism 9 (GraphPad Prism Software).

GraphPad Prism software version 9.3.1 was used for statistical analysis. Statistical significance was assessed by Kruskal-Wallis test, one-way ANOVA with mixed-effects model, two-way ANOVA with full model and main model. Statistical analysis was performed for A*01/S865 (n=7) and A*02/S269 (n=8) longitudinally analyzed CD8+ T cell responses in Figs.1a, b, 3c, 4a, b and Supplementary Figs.2a, 5ac, 7ce for n=28 subjects longitudinally followed in Fig.2a, for A*01/S865 (n=2) and A*02/S269 (n=3) T cell responses longitudinally followed in Fig.2c, for n=26 subjects in Fig.2b, for n=6 prepandemic samples Supplementary Fig.1c, for n=2 subjects in Supplementary Fig.3c, for n=7 at 3 months after 2nd vaccination, n=11 at 9 months after 2nd vaccination and n=11 at 3 months after 3rd vaccination in Fig.3a and Supplementary Fig.4b, for n=4 at 3 months after 2nd vaccination, n=8 at 9 months after 2nd vaccination and n=10 at 3 months after 3rd vaccination in Supplementary Fig.4b, for A*01/S865 (n=7) and A*02/S269 (n=6) longitudinally analyzed CD8+ T cell responses in Fig.3d, for n=8 at 3 months after 2nd vaccination, n=12 at 9 months after 2nd vaccination and n=11 at 3 months after 3rd vaccination in Fig.3b, for n=4 in Supplementary Fig.6a, for A*01/S865 (n=2) and A*02/S269 (n=2) longitudinally analyzed CD8+ T cell responses in Supplementary Fig.6b, for n=10 at 3 months after 2nd vaccination, n=12 at 9 months after 2nd vaccination and n=11 at 3 months after 3rd vaccination in Fig.4c, for n=10 at 3 months after 2nd vaccination, n=11 at 9 months after 2nd vaccination and n=11 at 3 months after 3rd vaccination in Fig.4d, for n=6 at 3 months after 2nd vaccination, n=12 at 9 months after 2nd vaccination and n=10 at 3 months after 3rd vaccination in Fig.4e, for n=6 at 3 months after 2nd vaccination, n=12 at 9 months after 2nd vaccination and n=11 at 3 months after 3rd vaccination in Fig.4f, for Omicron infection n=12, Delta infection n=2 and 4th vaccination n=5 longitudinally analyzed T-cell responses in Fig.5a, for Omicron infection n=11, Delta infection n=2 and 4th vaccination n=4 analyzed T cell responses in Fig.5b and in peak response in Supplementary Fig.8a, for Omicron infection n=12, Delta infection n=2 and 4th vaccination n=3 longitudinally analyzed T cell responses in Fig.6c, for Omicron infection n=11, Delta infection n=1 and 4th vaccination n=3 in Fig.6d, for Omicron infection n=6, Delta infection n=2 and 4th vaccination n=4 analyzed T cell responses after 1 month in Supplementary Fig.8a and Supplementary Fig.9b, for Omicron infection n=6, Delta infection n=2 and 4th vaccination n=4 analyzed T cell responses in Supplementary Fig.9a.

Further information on research design is available in theNature Research Reporting Summary linked to this article.

See the original post here:
COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation -...

NASA’s Solution to Stem Cell Production is Out of this World – BioSpace

NASA and Cedars-Sinai Medical Center are launching stem cells into space. In the study, funded by NASA and being conducted by scientists at Cedars-Sinai Medical Center in Los Angeles, the stem cells have been sent into space and will orbit for just over a months time to determine whether they grow differently without G-force.

A remotely controlled container of cells, with reagents and equipment needed to remotely sustain the cells, arrived at the International Space Station over the weekend. Two queries are presented alongside the launch details: do cells age differently in low orbit and can the Earthly challenges of stem cell growth amplification be overcome in space?

The human body is comprised of a full library of cell types, cataloged by specialty and location such as the striated cardiac muscles or the branching neurons in the brain. Each of these cells began as a raw stem cell and has developed in a particular manner. The cells can multiply to become a plentiful stem cell line under the correct conditions, but laboratory settings that would generate the quantity needed for medicinal purposes pose challenges that require innovative thinking.

Despite being featured in many biologic candidates currently under research and development and in clinical trials, mass-producing stem cells for use in these therapeutics isnt feasible. To prevent conglomeration or losing the stem cells at the bottom of a reactor tank, the bioreactor must be stirred at a rate that causes probable cell death. The end result is very few stem cells suitable for therapeutic and research use. By launching stem cells into space, the Cedars-Sinai research team is hoping to overcome these production limitations.

With stem cells, the possibilities and applications are increasing each day. They can work as models for testing drug safety and efficacy, thus reducing the burden placed on animal model research, be used as regenerative cells for those that have suffered damage as a result of injury or disease and even as a basic tool to help researchers further understand the human body.

By pushing the boundaries like this, its knowledge and its science and its learning, Clive Svendsen, executive director at the Cedars-Sinai Regenerative Medicine Institute, commented. Svendsen has sent a part of himself along with the project, as the donor of the stem cells.

Various other studies are being conducted by research teams around the globe in an effort to better understand the potential of stem cells.

Just last week, researchers from the University of Malta announced the launch of a similar mission that will be conducted aboard a SpaceX craft. The Maleth II project is the second installment of the Maleth Program that is designed to evaluate how human skin tissue cell genetics react to low earth orbit. A remotely controlled biocube will orbit the Earth for 60 days while the single cells are analyzed for changes.

The student researchers at the university are being directly supported by Maltas national Research, Innovation, Development Trust and the study itself is in collaboration with the Ministry of Foreign and European Affairs, Singleron Biotechnologies

See original here:
NASA's Solution to Stem Cell Production is Out of this World - BioSpace

The Human Trial Is A Documentary You Don’t Want To Miss [Review] – That Hashtag Show

Its not every day that a documentary comes out and is showing something that has been years in the making. But that could also just be because certain stories never get documented on video.

Well, The Human Trial is pulling the curtain back on a treatment that has been many years in the making.

More than a decade in the making, THE HUMAN TRIAL follows a groundbreaking clinical trial that peels back the headlines to show the sweat, passion, and sacrifice behind every breakthrough cure. In 2011, Lisa Hepner and her husband Guy Mossman heard about a radical stem cell treatment for diabetes, a disease that shockingly kills more than five million people each year. Driven by a desire to cure Lisa of her own type 1 diabetes (T1D), the filmmakers were given unprecedented, real-time access to a clinical trial only the sixth-ever embryonic stem cell trial in the world. What follows is an intimate journey with the patients and scientists who put themselves on the line to be first.

This documentary, from the outside, looks like any normal documentary. But The Human Trial shows something that has never been documented before.

The film says that the cure for Type 1 Diabetes is always 5 Years Away. And that is, in this case, actually true. But the biotech company featured in the film, Viacyte, wants to change that. They have been trying to find a way to use stem cells to cure the disease.

Now they show the actual device as well. And inside of the device, it has the stem cells in it. As for the device itself, it will act as a bio-artificial pancreas. Now, for trials like this, it usually takes a while to make sure the drug is going to be safe. And the documentary makes a point to mention that.

As for the actual trials themselves, we do get to see two different patients getting involved with the stem cell testing. Both Maren and Greg got their trials done at the University Of Minnesotas Medical Center. And for Maren, the stem cells started working for her within three weeks of implantation.

But there is another side to a trial like this, and that is funding. The team at Viacyte went all around the world to get more funding for their experimental drug. Then there is also removing the plants from the patient and testing them to see if they are working normally.

But all in all, this documentary shows what its like living with a disease like this, and the hard work that goes into making a cure.

One moment that did surprise me the most was watching Marens journey during the whole trial. She was the first person to do the trial, and it did seem like the cells were working for her. But when she found out the cells were not working, I was very shocked. And I was mostly shocked because she was the only one who had cells that were not working right. That is the case for most drug trials. They sometimes work, and other times they just dont work for one reason or another.

Learn more about The Human Trial here.

Go here to read the rest:
The Human Trial Is A Documentary You Don't Want To Miss [Review] - That Hashtag Show

Kite’s CAR T-cell Therapy Tecartus Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL) – Business Wire

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announces that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Tecartus (brexucabtagene autoleucel) for the treatment of adult patients 26 years of age and above with relapsed or refractory (r/r) B-cell precursor acute lymphoblastic leukemia (ALL). If approved, Tecartus will be the first and only Chimeric Antigen Receptor (CAR) T-cell therapy for this population of patients who have limited treatment options. Half of adults with ALL will relapse, and median overall survival (OS) for this group is only approximately eight months with current standard-of-care treatments.

Kites goal is clear: to bring the hope of survival to more patients with cancer around the world through cell therapy, said Christi Shaw, CEO, Kite. Todays CHMP positive opinion in adult ALL brings us a step closer to delivering on the promise that cell therapies have to transform the way cancer is treated.

Following this positive opinion, the European Commission will now review the CHMP opinion; the final decision on the Marketing Authorization is expected in the coming months.

Adults with relapsed or refractory ALL often undergo multiple treatments including chemotherapy, targeted therapy and stem cell transplant, creating a significant burden on a patients quality of life, said Max S. Topp, MD, professor and head of Hematology, University Hospital of Wuerzburg, Germany. If approved, patients in Europe will have a meaningful advancement in treatment. Tecartus has demonstrated durable responses, suggesting the potential for long-term remission and a new approach to care.

Results from the ZUMA-3 international multicenter, single-arm, open-label, registrational Phase 1/2 study of adult patients (18 years old) with relapsed or refractory ALL, demonstrated that 71% of the evaluable patients (n=55) achieved complete remission (CR) or CR with incomplete hematological recovery (CRi) with a median follow-up of 26.8 months. In an extended data set of all patients dosed with the pivotal dose (n=78) the median overall survival for all patients was more than two years (25.4 months) and almost four years (47 months) for responders (patients who achieved CR or CRi). Among efficacy-evaluable patients, median duration of remission (DOR) was 18.6 months. Among the patients treated with Tecartus at the target dose (n=100), Grade 3 or higher cytokine release syndrome (CRS) and neurologic events occurred in 25% and 32% of patients, respectively, and were generally well-managed.

About ZUMA-3

ZUMA-3 is an ongoing international multicenter (US, Canada, EU), single arm, open label, registrational Phase 1/2 study of Tecartus in adult patients (18 years old) with ALL whose disease is refractory to or has relapsed following standard systemic therapy or hematopoietic stem cell transplantation. The primary endpoint is the rate of overall complete remission or complete remission with incomplete hematological recovery by central assessment. Duration of remission and relapse-free survival, overall survival, minimal residual disease (MRD) negativity rate, and allo-SCT rate were assessed as secondary endpoints.

About Acute Lymphoblastic Leukemia

ALL is an aggressive type of blood cancer that develops when abnormal white blood cells accumulate in the bone marrow until there isnt any room left for blood cells to form. In some cases, these abnormal cells invade healthy organs and can also involve the lymph nodes, spleen, liver, central nervous system and other organs. The most common form is B cell precursor ALL. Globally, approximately 64,000 people are diagnosed with ALL each year, including around 3,300 people in Europe.

About Tecartus

Please see full FDA Prescribing Information, including BOXED WARNING and Medication Guide.

Tecartus is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of:

This indication is approved under accelerated approval based on overall response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

U.S. IMPORTANT SAFETY INFORMATION

BOXED WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITIES

Cytokine Release Syndrome (CRS), including life-threatening reactions, occurred following treatment with Tecartus. In ZUMA-2, CRS occurred in 91% (75/82) of patients receiving Tecartus, including Grade 3 CRS in 18% of patients. Among the patients who died after receiving Tecartus, one had a fatal CRS event. The median time to onset of CRS was three days (range: 1 to 13 days) and the median duration of CRS was ten days (range: 1 to 50 days). Among patients with CRS, the key manifestations (>10%) were similar in MCL and ALL and included fever (93%), hypotension (62%), tachycardia (59%), chills (32%), hypoxia (31%), headache (21%), fatigue (20%), and nausea (13%). Serious events associated with CRS included hypotension, fever, hypoxia, tachycardia, and dyspnea.

Ensure that a minimum of two doses of tocilizumab are available for each patient prior to infusion of Tecartus. Following infusion, monitor patients for signs and symptoms of CRS daily for at least seven days for patients with MCL and at least 14 days for patients with ALL at the certified healthcare facility, and for four weeks thereafter. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time. At the first sign of CRS, institute treatment with supportive care, tocilizumab, or tocilizumab and corticosteroids as indicated.

Neurologic Events, including those that were fatal or life-threatening, occurred following treatment with Tecartus. Neurologic events occurred in 81% (66/82) of patients with MCL, including Grade 3 in 37% of patients. The median time to onset for neurologic events was six days (range: 1 to 32 days) with a median duration of 21 days (range: 2 to 454 days) in patients with MCL. Neurologic events occurred in 87% (68/78) of patients with ALL, including Grade 3 in 35% of patients. The median time to onset for neurologic events was seven days (range: 1 to 51 days) with a median duration of 15 days (range: 1 to 397 days) in patients with ALL. For patients with MCL, 54 (66%) patients experienced CRS before the onset of neurological events. Five (6%) patients did not experience CRS with neurologic events and eight patients (10%) developed neurological events after the resolution of CRS. Neurologic events resolved for 119 out of 134 (89%) patients treated with Tecartus. Nine patients (three patients with MCL and six patients with ALL) had ongoing neurologic events at the time of death. For patients with ALL, neurologic events occurred before, during, and after CRS in 4 (5%), 57 (73%), and 8 (10%) of patients; respectively. Three patients (4%) had neurologic events without CRS. The onset of neurologic events can be concurrent with CRS, following resolution of CRS or in the absence of CRS.

The most common neurologic events (>10%) were similar in MCL and ALL and included encephalopathy (57%), headache (37%), tremor (34%), confusional state (26%), aphasia (23%), delirium (17%), dizziness (15%), anxiety (14%), and agitation (12%). Serious events including encephalopathy, aphasia, confusional state, and seizures occurred after treatment with Tecartus.

Monitor patients daily for at least seven days for patients with MCL and at least 14 days for patients with ALL at the certified healthcare facility and for four weeks following infusion for signs and symptoms of neurologic toxicities and treat promptly.

REMS Program: Because of the risk of CRS and neurologic toxicities, Tecartus is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Yescarta and Tecartus REMS Program which requires that:

Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylaxis, may occur due to dimethyl sulfoxide (DMSO) or residual gentamicin in Tecartus.

Severe Infections: Severe or life-threatening infections occurred in patients after Tecartus infusion. Infections (all grades) occurred in 56% (46/82) of patients with MCL and 44% (34/78) of patients with ALL. Grade 3 or higher infections, including bacterial, viral, and fungal infections, occurred in 30% of patients with ALL and MCL. Tecartus should not be administered to patients with clinically significant active systemic infections. Monitor patients for signs and symptoms of infection before and after Tecartus infusion and treat appropriately. Administer prophylactic antimicrobials according to local guidelines.

Febrile neutropenia was observed in 6% of patients with MCL and 35% of patients with ALL after Tecartus infusion and may be concurrent with CRS. The febrile neutropenia in 27 (35%) of patients with ALL includes events of febrile neutropenia (11 (14%)) plus the concurrent events of fever and neutropenia (16 (21%)). In the event of febrile neutropenia, evaluate for infection and manage with broad spectrum antibiotics, fluids, and other supportive care as medically indicated.

In immunosuppressed patients, life-threatening and fatal opportunistic infections have been reported. The possibility of rare infectious etiologies (e.g., fungal and viral infections such as HHV-6 and progressive multifocal leukoencephalopathy) should be considered in patients with neurologic events and appropriate diagnostic evaluations should be performed.

Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against B cells. Perform screening for HBV, HCV, and HIV in accordance with clinical guidelines before collection of cells for manufacturing.

Prolonged Cytopenias: Patients may exhibit cytopenias for several weeks following lymphodepleting chemotherapy and Tecartus infusion. In patients with MCL, Grade 3 or higher cytopenias not resolved by Day 30 following Tecartus infusion occurred in 55% (45/82) of patients and included thrombocytopenia (38%), neutropenia (37%), and anemia (17%). In patients with ALL who were responders to Tecartus treatment, Grade 3 or higher cytopenias not resolved by Day 30 following Tecartus infusion occurred in 20% (7/35) of the patients and included neutropenia (12%) and thrombocytopenia (12%); Grade 3 or higher cytopenias not resolved by Day 60 following Tecartus infusion occurred in 11% (4/35) of the patients and included neutropenia (9%) and thrombocytopenia (6%). Monitor blood counts after Tecartus infusion.

Hypogammaglobulinemia: B cell aplasia and hypogammaglobulinemia can occur in patients receiving treatment with Tecartus. Hypogammaglobulinemia was reported in 16% (13/82) of patients with MCL and 9% (7/78) of patients with ALL. Monitor immunoglobulin levels after treatment with Tecartus and manage using infection precautions, antibiotic prophylaxis, and immunoglobulin replacement.

The safety of immunization with live viral vaccines during or following Tecartus treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least six weeks prior to the start of lymphodepleting chemotherapy, during Tecartus treatment, and until immune recovery following treatment with Tecartus.

Secondary Malignancies may develop. Monitor life-long for secondary malignancies. In the event that one occurs, contact Kite at 1-844-454-KITE (5483) to obtain instructions on patient samples to collect for testing.

Effects on Ability to Drive and Use Machines: Due to the potential for neurologic events, including altered mental status or seizures, patients are at risk for altered or decreased consciousness or coordination in the 8 weeks following Tecartus infusion. Advise patients to refrain from driving and engaging in hazardous activities, such as operating heavy or potentially dangerous machinery, during this period.

Adverse Reactions: The most common non-laboratory adverse reactions ( 20%) were fever, cytokine release syndrome, hypotension, encephalopathy, tachycardia, nausea, chills, headache, fatigue, febrile neutropenia, diarrhea, musculoskeletal pain, hypoxia, rash, edema, tremor, infection with pathogen unspecified, constipation, decreased appetite, and vomiting. The most common serious adverse reactions ( 2%) were cytokine release syndrome, febrile neutropenia, hypotension, encephalopathy, fever, infection with pathogen unspecified, hypoxia, tachycardia, bacterial infections, respiratory failure, seizure, diarrhea, dyspnea, fungal infections, viral infections, coagulopathy, delirium, fatigue, hemophagocytic lymphohistiocytosis, musculoskeletal pain, edema, and paraparesis.

About Kite

Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, with manufacturing operations in North America and Europe. Kites singular focus is cell therapy to treat and potentially cure cancer. As the cell therapy leader, Kite has more approved CAR T indications to help more patients than any other company. For more information on Kite, please visit http://www.kitepharma.com. Follow Kite on social media on Twitter (@KitePharma) and LinkedIn.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the ability of Gilead and Kite to initiate, progress or complete clinical trials within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing and additional clinical trials, including those involving Tecartus; the risk that physicians may not see the benefits of prescribing Tecartus for the treatment of blood cancers; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and other factors are described in detail in Gileads Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Kite, and Gilead and Kite assume no obligation and disclaim any intent to update any such forward-looking statements.

U.S. Prescribing Information for Tecartus including BOXED WARNING, is available at http://www.kitepharma.com and http://www.gilead.com.

Kite, the Kite logo, Tecartus and GILEAD are trademarks of Gilead Sciences, Inc. or its related companies.

Visit link:
Kite's CAR T-cell Therapy Tecartus Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL) - Business Wire

ASCT No Longer Suitable for the Majority of Patients with DLBCL – OncLive

Most patients with diffuse large B-cell lymphoma do not derive significant benefit from treatment with autologous stem cell transplantation and better therapeutic options are currently available for this population.

Most patients withdiffuse largeB-celllymphoma (DLBCL) do not derive significant benefit from treatment with autologous stem cell transplantation (ASCT) and better therapeutic options are currently available for this population, according to a presentation at the 2022 Pan Pacific Lymphoma Conference.1

ASCT is lousy therapy in the modern era, said Jeremy S. Abramson, MD, MMSc. There are select patients who are still appropriate for ASCT, but that is a tiny minority in the modern era.

Abramson is the director of the Lymphoma Program and the Jon and Jo Ann Hagler Chair in Lymphoma at the Massachusetts General Hospital Cancer Center and an associate professor of medicine at Harvard Medical School, both in Boston, Massachusetts.

Salvage treatment with high-dose chemotherapy plus ASCT for patients with DLBCL who responded to their initial treatment often fails most patients, Abramson explained. Approximately 75% of patients who relapse do so within a year of receiving their frontline therapy, he noted, adding that approximately half of patients with relapsed/refractory DLBCL are not eligible for treatment with ASCT because of factors such as age or comorbidities.

Abramson cited data from the phase 3 ORCHARRDtrial (NCT01014208), which compared the efficacy of ofatumumabplus cisplatin, cytarabine, and dexamethasone (DHAP) followed by ASCT with that of rituximab (Rituxan)plus DHAP followed by ASCT among patients with relapsed/refractory DLBCL. The 2-year progression-free survival (PFS) rates were 24% and 26%, respectively (HR, 1.12; 95% CI, 0.89-1.42;P= .33). Moreover, the 2-year event-free survival (EFS) rates were 18% and 16%, respectively HR, 1.10; 95% CI, 0.90-1.36;P= .35).2

In another study, the phase 3 NCIC-CTG LY.12 trial (NCT00078949), investigators evaluated gemcitabine, dexamethasone, and cisplatin followed by ASCT vs DHAP in patients with relapsed/refractory aggressive lymphoma. Patients with B-cell lymphoma were also given rituximab. No significant differences were noted in 4-year EFS (HR, 0.99; 95% CI, 0.82-1.21; stratified log-rankP= .95), overall survival (OS; HR, 1.03; 95% CI, 0.83-1.28; P = .78), or PFS (HR, 0.99; 95% CI, 0.82-1.21; P = .95).3

More contemporary trials [such as] ORCHARRD and the NCIC-CTG LY.12 study [have shown] durable remissions in fewer than a quarter of patients. Abramson said. This is not good therapy.

Abramson said that CAR T-cell therapy is a superior choice for most patients with DLBCL. CAR T-cell agents have proven especially useful in the treatment of patients with primary refractory or early relapsed disease, he said.

In the phase ZUMA-7 trial (NCT03391466), the CAR T-cell agent axicabtagene ciloleucel (axi-cel; Yescarta) was evaluated against the standard of care of chemoimmunotherapy followed by high-dose chemotherapy with ASCT in patients who responded to the chemoimmunotherapy. The trial included patients with relapsed/refractory large B-cell lymphoma who were relapsed or refractory less than 1 year after their first-line treatment. Patients were randomly assigned 1:1 to receive either axi-cel (n = 180) or the standard of care (n = 179).4

At a median follow-up of 24.9 months, the median EFS in the axi-cel arm was 8.3 months (95% CI, 4.5-15.8) compared with 2.0 months (95% CI, 1.6-2.8) in the standard of care arm (HR, 0.40; 95% CI, 0.31-0.51; P < .001). The median PFS was 14.7 months (95% CI, 5.4-not estimable [NE]) vs 3.7 months (95% CI, 2.9-5.3) in the axi-cel and standard-of-care arms, respectively (HR, 0.49; 95% CI, 0.37-0.65). Notably, the median OS in the axi-cel arm was not reached (95% CI, 28.3-NE) vs 35.1 months (95% CI, 18.5-NE) in the standard-of-care arm (HR, 0.73; 95% CI, 0.53-1.01).

In terms of response, axi-cel was also superior to the standard of care. The overall response rate (ORR) was 83% vs 50%, respectively. Patients who received axi-cel also achieved a complete response (CR) rate of 65% compared with 32% among patients treated with the standard of care. Additionally, axi-cel was associated with improved quality of life as evaluated by patient reported outcomes.

The safety findings were mostly similar between the 2 arms; all patients in both arms experienced an adverse effect (AE) of any grade. Grade 3 or higher AEs occurred in 91% of patients and 83% of patients in the investigational and control arms, respectively. However, any grade cytokine release syndrome (CRS) was present in 92% of patients in the axi-cel arm and any grade neurologic AEs were more common in the axi-cel arm compared with the standard-of-care arm (60% vs 20%).

With CAR T-cell [therapy] we expect some CRS and neurotoxicity; we see a fair amount of that with axi-cel, Abramson said. The majority of patients did develop CRS, but it was severe in only 6%. Also, [most] patients developed neurologic toxicity, [but it was] severe in only 20%. And these toxicities are almost entirely reversible.

Another trial of a CAR T-cell agent, the phase 3 TRANSFORM trial (NCT03575351), examined the efficacy and safety of lisocabtagene maraleucel (liso-cel; Breyanzi) compared with the standard of care among patients with relapsed/refractory LBCL. Patients included in the trial had primary refractory or early relapsed disease.5

At a median follow-up of 6.2 months (range, 4.4-11.5), the median EFS was 10.1 (95% CI, 6.1-NE) compared with 2.3 months (95% CI, 2.2-4.3) in the liso-cel (n = 92) and standard-of-care arms (n = 92), respectively (HR, 0.35; 95% CI, 0.23-0.53; P < .0001). The median PFS was 14.8 months and 5.7 months, respectively (HR, 0.41; 95% CI, 0.25-0.66). The median OS was not reached vs 16.4 months, respectively (HR, 0.51; 95% CI, 0.26-1.00).

Similar to findings from the ZUMA-7 trial, liso-cel also resulted in a higher ORR compared with the standard of care (86% vs 48%). Patients in the liso-cel arm also achieved a CRR of 66% vs 39% in the standard-of-care arm. Over half of the standard-of-care arm (54%) crossed over to be treated with liso-cel and quality of life by patient reported outcomes again favored the CAR T-cell agent.

Treatment emergent AEs (TEAEs) occurred in nearly all patients in both arms (100% vs 99%). Grade 3 or higher TEAEs were slightly more common in the liso-cel arm (92%) compared with the standard-of-care arm (87%). Any grade CRS was present in 49% of patients who received liso-cel.

As was shown on ZUMA-7 not a single subset [of patients] favored high dose chemotherapy and ASCT over CAR T-cell [therapy] in this trial, Abramson said. This was an exceedingly well tolerated and entirely reversible therapy for patients who had a higher likelihood of cure with this treatment compared to standard of care.

Despite the convincing evidence against the use of ASCT, there is still a subset of patients with DLBCL for whom the treatment can be effective, argued Craig S. Sauter, MD, the director of the Blood and Marrow Transplant Programat the Cleveland Clinic in Cleveland, Ohio.

Value-based care has many facets, including not just end points [such as] EFS, PFS, and OS, but costs strain on limited resources within the space, patient quality of life, Sauter said. Financial toxicity is a real issue. Access to resources is a real issue. This will be an ongoing conversation.

Sauter went on to explain that access to CAR T-cell therapy is limited in the United States and across the world. The cost effectiveness of CAR T-cell agents in the second line is also unclear, Sauter noted. Axi-cel was found to have an $80,000 per quality adjusted life year vs standard of care and CAR T-cell therapy in general was shown to have up to a $2 million per quality adjusted life year compared with standard of care, he said.

Additionally, Sauter noted that ASCT has been shown to provide durable remissions in patients with DLBCL with a PET-positive partial response (PR). According to data from the Center for International Blood and Marrow Transplant Research, the median PFS for patients with DLBCL who received ASCT was comparable both among patients with and without early chemoimmunotherapy failure (P = .22).6

Stauter also pointed out that findings recently published in Blood showed that ASCT may actually be superior to CAR T-cell therapy for patients with DLBCL who are in PR following salvage chemotherapy. The 2-year PFS rates favored ASCT (52%) over CAR T-cell therapy (42%; P = .06). Moreover, the 2-year OS rates were 69% and 47%, respectively (P = .007).7

There may be a signal of improved durability of ASCT, Sauter said. But [these are] very different groups [of patients] and registry-level data that has to be taken with a grain of salt.

Originally posted here:
ASCT No Longer Suitable for the Majority of Patients with DLBCL - OncLive

Calendar of events, awards and opportunities – ASBMB Today

Every week, we update this list with new meetings, awards, scholarships and events to help you advance your career.If youd like us to feature something that youre offering to the bioscience community, email us with the subject line For calendar. ASBMB members offerings take priority, and we do not promote products/services. Learn how to advertise in ASBMB Today.

The American Society for Investigative Pathology, American Society for Matrix Biology and the histochemical Society have teamed up for a series of webinars about science careers. The next one will be at noon Eastern on July 27 titled "Career Options in Science Industry vs. Academia." It will have four panelists from Genentech, FENIX Group, GE Healthcare and the University of Saskatchewan. Learn more and register.

The National Institutes of Health Office of Research on Women's Health has a free quarterly lecture series titled "Diverse Voices: Intersectionality and the Health of Women." The July 28 event will include presentations from Heather Shattuck-Heidorn of the University of Southern Maine and Stephaun Wallace of the Fred Hutchinson Cancer Research Center. Register.

The National Institutes of Health is holding a series of listening sessions for members of the scientific community from certain populations. According to the event announcement, "Any member of the community or ally will have an opportunity to share their perspectives on workforce related challenges and solutions." NIH Acting Director Lawrence Tabak and others will be in attendance. See the August schedule below. Other listening sessions are slated for subsequent months. Register.

Aug. 3, 23 p.m.: Black/African American

Aug. 19, 910 a.m.: Hispanic/Latino

Aug. 22, 11 a.m. 12 p.m., Native American

This in-person meeting will be held Sept. 29 through Oct. 2 in Snowbird, Utah. Sessionswill cover recent advances and new technologies in RNA polymerase II regulation, including the contributions of non-coding RNAs, enhancers and promoters, chromatin structure and post-translational modifications, molecular condensates, and other factors that regulate gene expression. Patrick Cramer of the Max Planck Institute will present the keynote address on the structure and function of transcription regulatory complexes. The deadline for abstracts for talks is now July 21. The early registration deadline ($50 in savings) is Aug. 1. The deadline for poster presentation abstracts is Aug. 18. The regular registration deadline is Aug. 28.Learn more.

Most meetings on epigenetics and chromatin focus on transcription, while most meetings on genome integrity include little attention to epigenetics and chromatin. This conference in Seattle will bridge this gap to link researchers who are interested in epigenetic regulations and chromatin with those who are interested in genome integrity. The oral and poster abstract deadline and early registration deadline is Aug. 2. The regular registration deadline is Aug. 29.Learn more.

This five-day conference will be held Aug. 1418 in person in Cambridge, Massachusetts, and online. It will be an international forum for discussion of the remarkable advances in cell and human protein biology revealed by ever-more-innovative and powerful mass spectrometric technologies. The conference will juxtapose sessions about methodological advances with sessions about the roles those advances play in solving problems and seizing opportunities to understand the composition, dynamics and function of cellular machinery in numerous biological contexts. In addition to celebrating these successes, the organizers also intend to articulate urgent, unmet needs and unsolved problems that will drive the field in the future. The registration deadline was July 1, but you have until July 12 to register to participate virtually.Learn more.

For Discover BMB, the ASBMB's annual meeting in March in Seattle, we're seeking two types of proposals:

The American Physiological Society is hosting a free webinar that will cover polycystic ovary syndrome, an endocrine disorder associated with modestly elevated androgens, and hormone therapy for transmen, which elevates androgens greatly to achieve levels similar to those in cisgender men. The event announcement says: "The role that these two different concentrations play in cardiovascular physiology and pathophysiology remains unclear. Gaps and opportunities in basic research and clinical practice will be highlighted." The speaker will be Licy Yanes Cardozo, a physician-scientist at the University of Mississippi Medical Center. Learn more and register.

In May, the Howard Hughes Medical Institute launched a roughly $1.5 billion program to "help build a scientific workforce that more fully reflects our increasingly diverse country." The Freeman Hrabowski Scholars Program will fund 30 scholars every other year, and each appointment can last up to 10 years. That represents up to $8.6 million in total support per scholar. HHMI is accepting applications from researchers "who are strongly committed to advancing diversity, equity, and inclusion in science." Learn more.

Undergraduate students interested in interning at a U.S. Department of Energy laboratory in the spring must apply by Oct. 5. There are two programs to be aware of: the Science Undergraduate Laboratory Internships program and the Community College Internships program. In both cases, students work at national laboratories on research or technology projects supporting the agency's mission. All full-time students or recent grads are eligible for the first program, and community college students are eligible for the other. These are paid positions. Learn more.

The U.S. Department of Energy has expanded its opportunities for faculty members from historically underrepresented groupsto engage in research at national labs. The Visiting Faculty Program is intended to create partnerships between national labs and two-year colleges, minority-serving institutions and other colleges and universities nationwide. About 50% of participants are from MSI, and one-third of those are from historically Black colleges and universities. The deadline to apply is Oct. 5. Learn more.

The NASA Science Mission Directorate Bridge Program is intended to improve diversity, equity, inclusion and accessibility at NASA and in the broader STEM community. The agency seeks to partner with minority-serving institutions, primarily undergraduate institutions and Ph.D.-granting universities and provide paid research student positions "to transition science and engineering students from undergraduate studies into graduate schools and employment by NASA," according to the announcement. A virtual workshop will be held from Oct. 17 through Oct. 21. You have to formally express interest in attending. Learn more.

Save the date for the ASBMB Career Expo. This virtual event aims to highlight the diversity of career choices available to modern biomedical researchers. No matter your career stage, this expo will provide a plethora of career options for you to explore while simultaneously connecting you with knowledgeable professionals in these careers. Each 60-minute session will focus on a different career path and will feature breakout rooms with professionals in those paths. Attendees can choose to meet in a small group with a single professional for the entire session or move freely between breakout rooms to sample advice from multiple professionals. Sessions will feature the following five sectors: industry, government, science communication, science policy and other. The expo will be held from 11 a.m. to 5 p.m. Eastern on Nov. 2. Stay tuned for a link to register!

The Journal of Science Policy & Governanceand the National Science Policy Network issued a call for papersfor an issue containingpolicy ideas from the next generation of scientists. The submission deadline is Nov. 6. Theyencourage submissions "that highlight policy opportunities and audiences related to the 2022 U.S. midterm elections at the local, stateor national level as well as related foreign policy issues."Read the press release.

The ASBMB provides members with a virtual platform to share scientific research and accomplishments and to discuss emerging topics and technologies with the BMB community.

The ASBMB will manage the technical aspects, market the event to tens of thousands of contacts and present the digital event live to a remote audience. Additional tools such as polling, Q&A, breakout rooms and post event Twitter chats may be used to facilitate maximum engagement.

Seminars are typically one to two hours long. A workshop or conference might be longer and even span several days.

Prospective organizers may submit proposals at any time. Decisions are usually made within four to six weeks.

Propose an event.

If you are a graduate student, postdoc or early-career investigator interested in hosting a #LipidTakeover, fill out this application. You can spend a day tweeting from the Journal of Lipid Research's account (@JLipidRes) about your favorite lipids and your work.

The Federation of American Societies for Experimental Biology has launched the Career Advancement and Research Excellence Support (CARES) Program, which provides financial support for caregiving, enabling FASEB society members to continue their scientific training, professional development and career progression. Read the eligibility requirements and apply.

The International Union of Biochemistry and Molecular Biology is offering $500 to graduate students and postdocs displaced from their labs as a result of natural disaster, war or "other events beyond their control that interrupt their training." The money is for travel and settling in. Learn more and spread the word to those who could use assistance.

Originally posted here:
Calendar of events, awards and opportunities - ASBMB Today

Whitmer axes stem cell research, pregnancy center funding over abortion access concerns – MLive.com

Gov. Gretchen Whitmer used her veto pen on the states education budget Thursday to strike funding for pregnancy centers and stem cell research, saying that wording within the bill tried to create a gag rule concerning abortion.

Whitmer gave the final OK to a $19.6 billion K-12 education budget which contained an additional roughly $2 billion to universities and $530.3 million to community colleges, bringing the overall amount of the education budget to $22.2 billion July 14 at Mott Community College in Flint.

Word of her vetoes, however, came not too long after signing the budget and were targeted in two specific areas: stem cell research and crisis pregnancy centers.

RELATED: Whitmer signs $19.6B historic education budget, contains highest ever per-pupil investment

In a letter sent to lawmakers detailing the status of the final budget bill, Whitmer wrote that she was striking the items from the document as they harm womens health care.

These line items would create a gag rule preventing reproductive health-service providers from even mentioning abortion and otherwise make it harder for women to get the health care they need, she wrote. Any efforts to undermine a womans ability to make her own medical decisions with her trusted health-care provider will earn my disapproval. Women and doctors should be making health-care decisions not politicians.

Comprising her three vetoes were two $500,000 funding pots for pregnant and parenting student services, the wording for which put an explicit bar on mentioning abortion as a form of family planning, and $5 million in funding for stem cell/fetal tissue research.

Similar to the pregnancy service centers, wording surrounding the stem cell research grants would require universities agree to not conduct any research on aborted fetal tissue in order to make use of those funds.

On Friday, her administration again defended the move, with Whitmers Communication Director Bobby Leddy saying: While politicians in other states rush to restrict womens health care rights, even in instances of rape or incest, Michigan must remain a place where a womans ability to make her own medical decisions with her trusted health-care provider is respected.

The education budget signed earlier this week possesses the highest amount of per-pupil funding the state has ever allocated at $9,150 a child. Its a $450 increase per child, equaling a total cost increase of $630.5 million from the year prior. Theres also $214 in additional per-pupil funding for mental health and school safety for every child enrolled in a public school district.

More from MLive

Dixon and Rinke going tit for tat in gov. primarys final stretch

Meet the 9 Democrats vying to win the 13th U.S. House district seat

West Michigan clerk with forgery charge told not to oversee primary election

Want a say in Michigan education funding? Apply for governors parent council.

Ryan Kelley is confident he can beat Gretchen Whitmer and federal charges

View original post here:
Whitmer axes stem cell research, pregnancy center funding over abortion access concerns - MLive.com

Changing the World Through Philanthropy: UC San Diego Raises $3.05 Billion as Campaign for UC San Diego Concludes – University of California San Diego

From scholarships and fellowships to research to address the worlds greatest challenges, funds from more than 163,000 donors are making a difference locally, nationally and around the globe

The University of California San Diego has reached the conclusion of its landmark Campaign for UC San Diego, raising a total of $3.05 billion in philanthropic support over a span of 10 years. The funds have spurred a significant campus transformation, increased access with scholarships and fellowships for the next generation of leaders and expanded the universitys positive global impact with research that is addressing some of the worlds most pressing concerns.

Founded in 1960, UC San Diego is the nations youngest university to reach a multibillion-dollar fundraising goal in a single campaign, raising $1 billion more than the original $2 billion goal. More than 163,000 supporters designated charitable gifts and grants to over 450 different areas across campus, including UC San Diego Health and Scripps Institution of Oceanography. In the final year of the Campaign, which concluded on June 30, 2022, the campus raised a record-breaking $420 million, setting an upward trajectory for continued transformation and impact.

UC San Diego exceeded its initial campaign goal by more than $1 billion, raising a total of $3.05 billion.

The incredible support from our generous donors during the Campaign for UC San Diego has fueled a remarkable physical, intellectual and cultural transformation that has greatly enhanced the experiences of our students, our patients and our greater San Diego community, in addition to benefiting countless lives around the globe, said Chancellor Pradeep K. Khosla. Belief in UC San Diego as a force for change gave us three billion new reasons to keep exploring, to keep discovering and to keep impacting the world around us.

Campaign for UC San Diego volunteer leadership played a critical role in the success of the Campaign. Honorary co-chairs Joan and Irwin Jacobs, Ernest Rady and T. Denny Sanford set the foundation for the Campaigns success with gifts including $100 million from the Jacobs to establish the Jacobs Medical Center at UC San Diego Health, a commitment of $100 million from Ernest and Evelyn Rady for the Rady School of Management, and $200 million in total funds from Sanford to establish both the Sanford Stem Cell Clinical Center at UC San Diego Health and the T. Denny Sanford Institute for Empathy and Compassion.

In addition, more than 100 alumni and community members stepped up to lead this historic effort as members of the Campaign for UC San Diego Cabinet. Every cabinet member donated to the Campaign, generating support totaling $1 billion. More than half of the cabinet was composed of alumni, including cabinet co-chairs Ken Kroner, PhD 88, and Aryeh Bourkoff 95, who each supported the Campaign with multimillion-dollar gifts. Many members of the Cabinet are also current or former trustees of the UC San Diego Foundation.

Overall, alumni giving also went up significantly. More than 45,600 alumni donors gave $257 million in gifts, representing an increase of 1,300% over the last campaign.

We are so incredibly proud of how UC San Diego alumni have come together over the past decade to support their alma mater as a collective group, said Kimberley Phillips Boehm 82, UC San Diego Alumni president from 2020-22. This support is driving the universitys upward trajectory as it makes a difference for future generations of students, spurs innovative research, enhances medicine and transforms our campus.

Itzel Guadalupe Jimenez Jimenez 25, a Karen and Jeff Silberman Chancellors Associates Scholar, hopes to pursue a career in health care.

A key priority of the Campaign for UC San Diego was supporting its outstanding undergraduate and graduate students. The campus raised approximately $378 million for student support and success during the course of the Campaign, creating 315 new scholarship funds, including 163 endowed scholarships, which will remain in perpetuity. In addition, 184 new graduate fellowship funds were established, including 66 endowed fellowships.

A vital program established during the Campaign for UC San Diego was the Chancellors Associates Scholars Program (CASP). In addition to providing full tuition, fees and housing for high-achieving students from underrepresented communities, the program supports students with a wide range of services and opportunities to ensure that they thrive on campus and are fully engaged in academics, student life and in university experiences. Supported by $8 million in private support, the scholarship has been awarded to more than 1,800 students.

Itzel Guadalupe Jimenez Jimenez 25, a Karen and Jeff Silberman Chancellors Associates Scholar and Lincoln High School graduate, chose to major in Spanish literature, recalling a childhood memory of being in an emergency room while her mother struggled to overcome language barriers. She plans to pursue a career as a translator in the health care industry with the goal of helping all patients get the care they need.

The Chancellors Associates Scholarship has given me a chance to study and pursue my dream career, said Jimenez Jimenez. Receiving this scholarship really means a lot to me because it is one less thing my family has to worry about.

Jacobs Fellow Marwa Abdalla is a doctoral candidate focused on anti-Black and anti-Muslim racisms.

In 2021, Chancellor Khosla announced the Chancellors Scholarship and Fellowship Challenge to boost funding for students on campus. Gifts to undergraduate scholarships, graduate fellowships and health-related professional school scholarships were matched 1:2 by the chancellor. At the close of the challenge, a total of $21 million was raised in gifts and matching funds.

Jerri-Ann and Gary E. Jacobs 79, pledged a total of $2 million to student support as part of the challenge, including adding $1 million to the existing Jerri-Ann and Gary E. Jacobs Endowed Fellowship Fund. Jacobs Fellow Marwa Abdalla is a second-year doctoral candidate in the Department of Communication whose research is focused on anti-Black and anti-Muslim racisms, media representations of Islam and Muslims, and how legacies of imperialism and Orientalism continue to inform conservative and progressive politics.

Not only is it an honor to be recognized with this fellowship, said Abdalla, but the support allows me to focus on connecting my research to national and local efforts aimed at challenging racism in all its forms.

In addition, several other alumni donors have supported undergraduate scholarships at UC San Diegooften with the goal of boosting equity, diversity and inclusion on campus. Kimberley Phillips Boehm 82 and Marcus Boehm 83 donated $1 million to support the PATHways to STEM through Enhanced Access and Mentorship Program (PATHS), which is structured to provide critical mentorship and financial support for undergraduate UC San Diego STEM students from under-resourced communities.

UC San Diego received the largest scholarship gift for scholar-athletes in its history from LionTree, an independent investment and merchant bank founded by alumnus and Campbain Cabinet co-chair Aryeh Bourkoff.

UC San Diego also received the largest scholarship gift for scholar-athletes in its history from independent investment and merchant bank LionTree, which was founded by alumnus Aryeh Bourkoff. RIMAC Arena was renamed LionTree Arena in recognition of the gift.

To learn more about the Campaigns remarkable impact on student support and success, such as contributions to the Triton Food Pantry and more, visit the Campaign website to read about other student support gifts.

Fueled by philanthropic support, UC San Diego ranked 4th among public research institutions in the U.S. by Nature Index for high-quality science, based on research publications in highly selective science journals in 2020. The campus ranked 10th among all U.S. universities. Research is driving innovation and discoveries in a wide range of areas at UC San Diego, from exploring active genetics as a means to control malaria worldwide to developing actionable strategies for adapting to climate change.

Kicking off the public phase of the Campaign for UC San Diego in 2017, alumnus Taner Halcolu 96 committed $75 million to launch the Halcolu Data Science Institute (HDSI) and support data science initiatives on campus. Within the first year, the institute established itself as one of the largest academic data science programs in the nation.

Looking to the sky, scientists are closer to understanding the conditions of the universe moments after its inception, thanks to commitments totaling nearly $100 million from the Simons Foundation over the course of the Campaign. The funds supported design, construction and operations of the Simons Observatory in Chiles Atacama Desert.

The Goeddel Family Technology Sandbox is providing access and training to master leading-edge biotech industry instruments.

In the UC San Diego School of Social Sciences, researchers are working to better understand and address the factors that lead to homelessness. With philanthropic support from Phyllis and Dan Epstein and Hanna and Mark Gleiberman, UC San Diego recently launched the regions first large-scale, university-based research and data hub focused exclusively on homelessness. The Homelessness Hub at UC San Diego will serve as a non-partisan hub for research, education, policy and action on homelessness.

Philanthropic support like this from the Epsteins and Gleibermans is helping drive a wide range of critical work in the social sciencesfrom homelessness to immigration and racial inequitythat benefit our society now and will shape the future for generations to come, said Dean of the School of Social Sciences Carol Padden.

Alumnus David Goeddel 72, and his wife, Alena, established the Goeddel Family Technology Sandbox with a $7.5 million gift. The new, innovative campus facility, also part of a 10-year public-private partnership with Thermo Fisher Scientific, is designed to help set UC San Diego graduates ahead in the biotech industry, providing them with access and training to master leading-edge industry instruments which are often cost-prohibitive for college campuses. The Sandbox will drive research, education and innovation in emerging areas including genome engineering, mass spectrometry, flow cytometry, light microscopy, cryo-electron microscopy (cryo-EM) and data science.

The Goeddel Family Technology Sandbox will further enhance UC San Diegos profile as one of the nations top places to study the biological sciences and as the top producer of talent to fuel innovation in life sciences in both academia and industry, said Dean of the School of Biological Sciences Kit Pogliano.

The Joe and Clara Tsai Foundation provided a major gift to the 21st Century China Center at the School of Global Policy and Strategy (GPS) to expand its data-based research, policy engagement and education on U.S.-China relations. The largest donation ever received by GPS and its research centers, the gift provided an endowment that helped cement the center as the leading U.S. academic center and policy think tank that produces scholarly research and informs policy discussions related to China.

The Center for Climate Change Impacts and Adaptation is addressing the effects of climate change, such as flooding in Imperial Beach.

The Center for Climate Change Impacts and Adaptation, created in 2015 with a $5 million commitment from Richard and Carol Dean Hertzberg, is focused on a new chapter of climate research that considers how society can address the consequences of climate change that are already unfolding. The center draws on the expertise of climate scientists as well as experts ranging from economists, sociologists and engineers to urban planners and political scientists to document climate change impacts and devise practical solutions.

In 2017, the late Franklin Antonio 74, became the first alumnus to have a building named in his honor after making a $30 million gift to support the Jacobs School of Engineering. Franklin Antonio Hall, a 200,000-square-foot engineering building will open in fall of 2022. The building will feature 13 collaboratoriesspaces that will house multiple professors and their respective research groups to encourage interdisciplinary collaborations to address some of societys most critical issues.

As UC San Diego drives leading-edge innovation and discoveries, the Institute for Practical Ethics was established in the School of Arts and Humanities with $1 million from Joel and Ann Reed to help close the gap between the pace of innovation and societys ability to deal with these advances responsibly.

The Bill & Melinda Gates Foundation granted $1.4 million to study next-generation gene drive systems based on CRISPR technology, which could potentially be used to curb the spread of mosquito-borne pathogens such as malaria. The funding was also designated to help address the social and ethical challenges of moving these techniques from the lab into the wild. In total, the Gates Foundation has provided nearly $62 million in total grant funding over the course of the Campaign to a wide range of campus areas including public health, medicine and education.

During the course of the Campaign, 123 new endowed faculty chairs were established. Increasing the number of endowed chairs is a priority at UC San Diego, as they provide a perpetual source of funds for research and scholarly work by chair-holders, playing an important role in attracting and retaining academic leaders. The effort to grow the number of endowed chairs on campus was bolstered by the UC San Diego Chancellors Endowed Chair and Faculty Fellowship Challenge, wherein Chancellor Khosla matched $500,000 eligible endowed chair gifts. A University of California-sponsored Presidential Match for Endowed Chairs was launched in 2014 and helped grow support for endowed chairs even further. Endowed chairs were created throughout campus including the Dr. Harry M. Markowitz Endowed Chair in Finance and Investing and the Duane A. Nelles Jr. Endowed Chair in Corporate Governance at the Rady School of Management, the Conrad Prebys Presidential Chair in Music, the Edward A. Frieman Presidential Chair in Climate Sustainability and many more.

To learn more about the groundbreaking research and innovation taking place thanks to the support of philanthropic partnersfrom the depths of the ocean to the universe above, please visit the Campaign for UC San Diego website.

UC San Diego Health is dedicated to advancing medicine through breakthrough discoveries, including pioneering firsts in surgery, imaging, cancer treatment and cardiovascular care. UC San Diego Health is ranked 1st in San Diego and 5th in California for health care by U.S. News & World Report, positioning it among the nations best hospitals.

During the Campaign, UC San Diego Health went through an immense transformation and expansion. Science research was bolstered by the 2014 opening the Altman Clinical and Translational Research Institute, which translates scientific discoveries into drugs and therapies. Jacobs Medical Center then opened in 2016, followed in 2018 by the Koman Family Outpatient Pavilion, which includes eight surgery suites, basic and advanced imaging, physical therapy and pain management plus infusion and apheresis services.

Jacobs Medical Center at UC San Diego Health opened in 2016.

Over the last decade, UC San Diego Health has undergone a tremendous transformation that has benefited patients throughout the region with enhanced treatments and better facilities, said UC San Diego Health CEO Patty Maysent. We are so grateful to our donors who have generously partnered with us in providing the best possible care for patients, from building the leading-edge facilities to recover and heal, to offering new and innovative treatments of promise.

Thanks to the support of Irwin and Joan Jacobs, as well as many other generous donors, Jacobs Medical Center has now served the community with specialty patient care for over five years. It is home to the A. Vassiliadis Family Pavilion for Advanced Surgery, the Pauline and Stanley Foster Pavilion for Cancer Care and the Rady Pavilion for Women and Infants.

Alumnus Aaron Sathrum, MS 06, PhD 11, can attest to the impact of the care available at Jacobs Medical Center. All three of his children were born at the facility, but his youngest son, Niels, was born at only 26 weeks in the medical centers Rady Pavilion for Women and Infants. Niels was only 2.2 pounds and suffered from collapsed lungs, an intestinal perforation, a brain hemorrhage, jaundice and a blood infection.

The challenges ahead were great, but with a treatment plan in place, the help of the Jacobs Medical Center team and the resilience of our son, we were released earlier than expected, said Sathrum. Although we spent over half of the year in the hospital, unsure of what was to come next, there is no better feeling than knowing our family is together.

All three of the Sathrum familys children were born at Jacobs Medical Center.

Niels is now over a year old. Every day I look at himIm grateful, said Sathrum.

During the Campaign for UC San Diego, many donors helped advance treatments for cancer. Centers and research initiatives established at UC San Diego Health included the Hanna and Mark Gleiberman Head and Neck Cancer Center, the Dean-Hertzberg Breast Cancer Database System (BCDS) at Moores Cancer Center and the Comprehensive Breast Health Center supported by Rebecca Moores. As a result, patients are better equipped with leading-edge technologies and treatments to overcome cancer.

In addition, donors came together to support ocular health and fight eye disease and blindness. Andrew J. Viterbi gave $50 million to name the Viterbi Family Department of Ophthalmology and the Viterbi Family Vision Research Center, which also created six new endowed faculty chairs. The Nixon Visions Foundation, led by UC San Diego alumnus Brandon Nixon 85, and his wife, Janine, established the Nixon Visions Foundation Macular Dystrophy-PRPH2 Research Fund to treat macular dystrophy, a condition for which there is no cure. And, continuing her decades-long legacy of support for eye health, Darlene Shiley gave $10 million for the clinical space expansion of the Shiley Eye Institute at UC San Diego Health, which will bring a new era of vision care and research with increased clinical capacity and research infrastructure.

The Campaign also ushered in a new era of public health research, education and advances with a $25 million gift from the Dr. Herbert and Nicole Wertheim Family Foundation that established the Herbert Wertheim School of Public Health and Human Longevity Science. The Herbert Wertheim School of Public Health is working to promote healthier populations on a local, national and global scale.

Daniel and Phyllis Epstein also recently established the Epstein Family Alzheimers Research Collaborative at UC San Diego and USC, with $25 million going to each institution to spark new collaborative efforts to discover effective therapies for Alzheimers disease.

Philanthropic funds are fueling advancements in treatments and cures for disease that will ultimately benefit people around the world.

Establishing endowed faculty chairs was a key priority of the campaign, with 40 created in the health sciences. Iris and Matthew Strauss, longtime supporters of cancer research and patient care at Moores Cancer Center at UC San Diego Health established the Iris and Matthew Strauss Chancellors Endowed Chair in Head and Neck Surgery to support excellence in research, education and clinical care.

Endowed faculty chairs play a critical role in helping to attract and retain the top minds in science and medicine, said Steven Garfin, MD, interim vice chancellor for Health Sciences and interim dean of the UC San Diego School of Medicine. We are so grateful to our donors who have supported UC San Diego in the discovery and development of better treatments and new cures for devastating diseases and medical conditions.

Looking to the future, Price Philanthropies Foundation and the Price family donated $10 million to support a new 250,000-square-foot outpatient pavilion at the UC San Diego Medical Centers Hillcrest campus, which is currently undergoing revitalization. The outpatient pavilion is anticipated to open in 2025.

To read more about the incredible medical advancements made possible with philanthropy, including those to battle conditions such as Parkinsons, traumatic brain injury and more, please visit the Campaign for UC San Diego website.

Over the last decade, UC San Diego has undergone a significant physical, intellectual and cultural transformation, with the goal of becoming a premier destination for students, employees, patients and community members. In 2016, construction started on the 11-mile extension of the UC San Diego Blue Line trolley. When two new trolley stations opened on campus in 2021, the university became connected to the region like never before, and donors have stepped up to help open the campus more broadly to the region.

UC San Diego Park & Market, the universitys long anticipated presence in downtown San Diego opened earlier this year.

In addition to supporting research to address Alzheimers disease and homelessness, Daniel and Phyllis Epstein provided $10 million for the soon-to-be-opened Epstein Family Amphitheater. The new state-of-the-art 2,850-seat campus venue, which is steps from the Central Campus station of the UC San Diego Blue Line trolley, will open in October 2022, showcasing everything from classical performances and theatrical dance to rock concerts.

Steps away from the Blue Line trolleys downtown stop is UC San Diego Park & Market, which opened in spring of 2022. Located on a full city block at the intersection of Park Boulevard and Market Street in San Diegos East Village neighborhood, Park & Market is a social and intellectual hub for civic engagement, learning and collaboration for the entire community.

Longtime UC San Diego donor Malin Burnham and his wife, Roberta, committed $3 million to support the partnership between the Burnham Center for Community Advancement and UC San Diego in their creation of a civic collaboratory at Park & Market focused on bringing together great minds to advance the region. David and Claire Guggenheim also gave $1 million to the project, establishing their namesake David and Claire Guggenheim Theatre, a 225-seat black box theater to be used for a wide range of performances and teaching.

The internationally renowned Stuart Collection at UC San Diego also received a $1 million gift from Mary Looker, which established an endowment to help foster the growth of the self-supported collection for years to come. Composed of 22 unique works which have been sprouting across campus over the past four decades, the Stuart Collection represents an impressive assemblage of public art by celebrated contemporary artists such as Robert Irwin, Do Ho Suh, Bruce Nauman and Kiki Smith.

Fallen Star by Do Ho Suh is a part of the unique Stuart Collection, which received $1 million in endowment support.

The arts are deeply rooted in the identity of our university, from our internationally recognized arts departments and highly-ranked degree programs to our affiliations with world-renowned artistic partners, said Executive Vice Chancellor Elizabeth H. Simmons. We are grateful to our generous donors who have helped us build upon our traditions of aesthetic experimentation and public engagement, establishing our campus as an arts destination and making us a leader amongst our peer institutions.

In support of the UC San Diego Library, which is widely utilized by the local community, UC San Diego Foundation trustee and alumna Sally T. WongAvery 75 donated $10 million through the Avery-Tsui Foundation to support East Asian scholarship and collections. In recognition of the gift, UC San Diego renamed its Biomedical Library as the Sally T. WongAvery Library. In addition, thanks to a $3 million lead donation from the late Audrey Geisel, UC San Diegos iconic Geisel Library is getting a much-needed interior update to enhance the user experience with modern, collaborative spaces.

Furthering the universitys impact in the community and changing the way education is delivered to students living in underserved areas, Robert and Allison Price, through Price Philanthropies, donated $6 million in 2015 to UC San Diegos Birch Aquarium at Scripps Institution of Oceanography to establish the Price Philanthropies Ocean Science Education Fund. The endowment created a new education program to inspire student engagement in science and interest in STEM fields, as well as to provide a blueprint for how teachers, informal science educators and scientists can work together to transform science education.

The Price Philanthropies Ocean Science Education Fund is supporting science education programs at Birch Aquarium at Scripps Institution of Oceanography.

To read more about the Campaign for UC San Diego and the incredible impact of our donors generous gifts over the last decade, please visit the Campaign for UC San Diego website.

Go here to read the rest:
Changing the World Through Philanthropy: UC San Diego Raises $3.05 Billion as Campaign for UC San Diego Concludes - University of California San Diego

Subang Jaya Medical Centre Applauded by Frost & Sullivan for Its Leadership Position in the Malaysian Hospital Industry – Canada NewsWire

SJMC is well positioned to drive the private hospital space into its next growth phase, capturing market share and sustaining its leadership in the coming years.

SAN ANTONIO, July 12, 2022 /CNW/ --Recently, Frost & Sullivan researched the Malaysian hospital industry and, based on its analysis results, recognizes Subang Jaya Medical Centre(SJMC) with the 2022 Company of the Year Award. The company is accredited by Joint Commission International (JCI) and the Malaysian Society for Quality in Health (MSQH), and its medical laboratories are certified by the International Organization for Standardization (ISO). As part of the Ramsay Sime Darby Health Care Group, SJMC ensures its medical practitioners and administrative staff provide top-notch private healthcare. The multi-disciplinary private healthcare service provider has a capacity of 444 beds, a long history, and remarkable milestones, all contributing to its leadership position in Malaysia's medical industry. SJMC is the first to conduct the following in Malaysia:

SJMC's vision involves developing partnerships to provide the best private healthcare to help patients lead better lives. The company connects deep-seated domain and operational knowledge with advanced services to deliver care during the COVID-19 pandemic. The hospital adapts real-time reverse transcription polymerase chain reaction tests to reduce the waiting time for patient admission. With Home Connect, home care services are available to patients who cannot commute to the hospital, either because of the difficulty in physically commuting or as a precaution against COVID-19. The service allows nurses or physiotherapists to visit patients in their homes, especially after surgery. In addition, the service includes home delivery of long-term medication. The hospital's Home Connect service is convenient and creates a shift in modern healthcare because it complies with clinical care standards, and provides patients and their families with peace of mind.

According to Siddharth Shah, Research Manager for Frost & Sullivan, "SJMC seamlessly assimilates into the post-pandemic private medical care scene and emerges as a leader in providing contactless home care as a permanent mode of care delivery, an extensive offering unique to the market."

SJMC's selected rehabilitation services, such as physiotherapy and palliative care, are available for home care visits. Its teleconnect center provides 24-hour convenience of obtaining medical advisory services over the phone or through WhatsApp to improve customer service. Moreover, the hospital became the first in the country to offer the latest tomography services for efficient and high-precision cancer treatment as well as digital PET/CT services. It conducts nursing training initiatives to prevent errors in medication and intravenous care, uphold therapy and medication safety standards, and support the continuous development of its healthcare staff. SJMC has a leadership legacy; therefore, its compelling value proposition underpins its sustained success. The company's brand equity, unwavering focus on leadership, best practices implementation, customer-centric focus, and continual and proactive innovation contribute to its sustained success and leading market position.

"SJMC meets with patients to assess their specific needs and develop tailored solutions with roadmaps for seamless execution. This foundational approach establishes ongoing trust with customers for long-lasting relationships extending throughout the service lifecycle," explained Azza Fazar, Best Practices Research Analyst for Frost & Sullivan. "The company remains a trusted partner, earning a reputation for offering the overall best care in the hospital space."

Each year, Frost & Sullivan presents a Company of the Year award to the organization that demonstrates excellence in terms of growth strategy and implementation in its field. The award recognizes a high degree of innovation with products and technologies and the resulting leadership in terms of customer value and market penetration.

Frost & Sullivan Best Practices Awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analystscompare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:

Kala Mani. S. P: +603-2023 2037 E: [emailprotected]

About Subang Jaya Medical Centre

The hallmarks that determine the provision of excellent healthcare are the breadth and depth in clinical expertise and the latest in medical technology, top-notch or trail-blazing services, integrated healthcare for end-to-end patient care, high survival rates, best patient safety practices, internationally recognized accreditation, high calibre and well-trained staff and vibrant patient support group activities.

All the above and more is what made Subang Jaya Medical Centre, an award-winning multi-disciplinary and tertiary care private hospital with over 400 beds, a well-trusted and one of Asia-Pacific's most formidable standard-bearers for quality care for well over a quarter of a century since 1985.

SJMC is nestled in the bustling city of Subang Jaya in Selangor Darul Ehsan, a 30-minute drive to the Kuala Lumpur city centre and the Kuala Lumpur International Airport via major highways. Subang Jaya is one of Malaysia's largest cities, in terms of population and economic activity. SJMC provides comprehensive and complex care in all specialties and is a tertiary referral hospital, receiving local patient referrals from within Malaysia as well as international patients from the Asia-Pacific region.

Subang Jaya Medical Centre 1 Jalan SS12/1A Subang Jaya 47500 Selangor Darul Ehsan Malaysia

T: +6 03 5639 1212 (24-hour Careline) WhatsApp: +6 019 317 1818 (for appointment) E: [emailprotected] Website: http://www.subangjayamedicalcentre.com

SOURCE Frost & Sullivan

See the rest here:
Subang Jaya Medical Centre Applauded by Frost & Sullivan for Its Leadership Position in the Malaysian Hospital Industry - Canada NewsWire